OBJECTIVE: To determine the prevalence of antimicrobial resistance to macrolide antimicrobials or rifampin in Rhodococcus equi isolates and to describe treatment outcome in foals infected with antimicrobial-resistant isolates of R equi. DESIGN: Cross-sectional study. SAMPLE POPULATION: 38 isolates classified as resistant to macrolide antimicrobials or rifampin received from 9 veterinary diagnostic laboratories between January 1997 and December 2008. PROCEDURES: For each isolate, the minimum inhibitory concentration of macrolide antimicrobials (ie, azithromycin, erythromycin, and clarithromycin) and rifampin was determined by use of a concentration-gradient test. Prevalence of R equi isolates from Florida and Texas resistant to macrolide antimicrobials or rifampin was determined. Outcome of antimicrobial treatment in foals infected with antimicrobial-resistant isolates of R equi was determined. RESULTS: Only 24 of 38 (63.2%) isolates were resistant to >or= 1 antimicrobial. Two isolates were resistant only to rifampin, whereas 22 isolates were resistant to azithromycin, erythromycin, clarithromycin, and rifampin. The overall prevalence of antimicrobial-resistant isolates in submissions received from Florida and Texas was 3.7% (12/328). The survival proportion of foals infected with resistant R equi isolates (2/8 [25.0%]) was significantly less, compared with the survival proportion in foals that received the same antimicrobial treatment from which antimicrobial-susceptible isolates were cultured (55/79 [69.6%]). Odds of nonsurvival for foals infected with resistant R equi isolates were 6.9 (95% confidence interval, 1.3 to 37) times the odds for foals infected with susceptible isolates. CONCLUSIONS AND CLINICAL RELEVANCE: Interpretation of the results emphasized the importance of microbiological culture and antimicrobial susceptibility testing in foals with pneumonia caused by R equi.
OBJECTIVE: To determine the prevalence of antimicrobial resistance to macrolide antimicrobials or rifampin in Rhodococcus equi isolates and to describe treatment outcome in foals infected with antimicrobial-resistant isolates of R equi. DESIGN: Cross-sectional study. SAMPLE POPULATION: 38 isolates classified as resistant to macrolide antimicrobials or rifampin received from 9 veterinary diagnostic laboratories between January 1997 and December 2008. PROCEDURES: For each isolate, the minimum inhibitory concentration of macrolide antimicrobials (ie, azithromycin, erythromycin, and clarithromycin) and rifampin was determined by use of a concentration-gradient test. Prevalence of R equi isolates from Florida and Texas resistant to macrolide antimicrobials or rifampin was determined. Outcome of antimicrobial treatment in foals infected with antimicrobial-resistant isolates of R equi was determined. RESULTS: Only 24 of 38 (63.2%) isolates were resistant to >or= 1 antimicrobial. Two isolates were resistant only to rifampin, whereas 22 isolates were resistant to azithromycin, erythromycin, clarithromycin, and rifampin. The overall prevalence of antimicrobial-resistant isolates in submissions received from Florida and Texas was 3.7% (12/328). The survival proportion of foals infected with resistant R equi isolates (2/8 [25.0%]) was significantly less, compared with the survival proportion in foals that received the same antimicrobial treatment from which antimicrobial-susceptible isolates were cultured (55/79 [69.6%]). Odds of nonsurvival for foals infected with resistant R equi isolates were 6.9 (95% confidence interval, 1.3 to 37) times the odds for foals infected with susceptible isolates. CONCLUSIONS AND CLINICAL RELEVANCE: Interpretation of the results emphasized the importance of microbiological culture and antimicrobial susceptibility testing in foals with pneumonia caused by R equi.
Authors: Jennifer M Willingham-Lane; Londa J Berghaus; Roy D Berghaus; Kelsey A Hart; Steeve Giguère Journal: Appl Environ Microbiol Date: 2019-03-22 Impact factor: 4.792
Authors: Laura Huber; Steeve Giguère; Nathan M Slovis; Craig N Carter; Bonnie S Barr; Noah D Cohen; Justine Elam; Erdal Erol; Stephan J Locke; Erica D Phillips; Jacqueline L Smith Journal: Antimicrob Agents Chemother Date: 2018-12-21 Impact factor: 5.191
Authors: Sonsiray Álvarez-Narváez; Laura Huber; Steeve Giguère; Kelsey A Hart; Roy D Berghaus; Susan Sanchez; Noah D Cohen Journal: Microbiol Mol Biol Rev Date: 2021-04-14 Impact factor: 11.056
Authors: J S Weese; S Giguère; L Guardabassi; P S Morley; M Papich; D R Ricciuto; J E Sykes Journal: J Vet Intern Med Date: 2015-03-17 Impact factor: 3.333
Authors: Alexandra J Burton; Steeve Giguère; Tracy L Sturgill; Londa J Berghaus; Nathan M Slovis; Jeremy L Whitman; Court Levering; Kyle R Kuskie; Noah D Cohen Journal: Emerg Infect Dis Date: 2013-02 Impact factor: 6.883
Authors: Carla C C R de Carvalho; Sofia S Costa; Pedro Fernandes; Isabel Couto; Miguel Viveiros Journal: Front Physiol Date: 2014-04-04 Impact factor: 4.566